Reporting suspected adverse reactions following vaccination against mpox (monkeypox)
16 December 2022 – The Bavarian Nordic smallpox vaccine, which is authorised in Europe, is also effective against mpox (monkeypox). It has been available in Switzerland as a preventive measure for high-risk individuals since November 2022. Suspected adverse drug reactions should be reported to Swissmedic.
For more information, see here.